Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 8, Issue 1, Pages 95-109Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.8.1.95
Keywords
endothelin-1; endothelin receptor antagonist; pulmonary arterial hypertension
Categories
Ask authors/readers for more resources
Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition. Sitaxsentan, a selective enclothelin-A receptor antagonist, is an effective, safe and well-tolerated enclothelin receptor antagonist for the treatment of PAH in adult patients. Multi-center, randomized, placebo-controlled clinical trials have demonstrated that sitaxsentan has beneficial effects on exercise capacity (i.e., 6-min walk distance), functional class and hemodynamic parameters in PAH patients. Sitaxsentan has a low incidence of acute hepatotoxicity. Patients on concomitant warfarin require a decrease in warfarin dose to maintain a therapeutic international normalized ratio. The demonstration of clinical efficacy and low incidence of acute hepatotoxicity support the potential use of sitaxsentan for the treatment of PAH.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available